Form 13-F position report

STOKE THERAPEUTICS INC COM

Reported by Birchview Capital LP

STOK CUSIP 86150R107 Manager CIK 0001618205

Reported 260,000 shares, up 50,000 (23.8%) from the prior quarter.

Reported value 67.2%; share count 23.8% vs. the prior quarter.

Added
% of reported 13F value 4.83% This manager · Q4 2025
Shares 260,000 Quarter-end amount reported
Reported value $8,252,400 Fair value at quarter end
Consecutive quarters held 24 Through Q4 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 382000
2021-12-31 360000
2022-03-31 316000
2022-06-30 198000
2022-09-30 193000
2022-12-31 138000
2023-03-31 125000
2023-06-30 903550
2023-09-30 334900
2023-12-31 1104600
2024-03-31 2835000
2024-06-30 2837100
2024-09-30 2580900
2024-12-31 2316300
2025-03-31 1396533
2025-06-30 2383500
2025-09-30 4935000
2025-12-31 8252400
2026-03-31 6837600
2026-06-30 5827759

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for STOKE THERAPEUTICS INC COM held by Birchview Capital LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 178,110 -31,890 (-15.2%) 2.73% $5,827,759 2026-08-14
Q1 2026 Reduced 210,000 -50,000 (-19.2%) 3.89% $6,837,600 2026-05-15
Q4 2025 Added 260,000 +50,000 (23.8%) 4.83% $8,252,400 2026-02-13
Q3 2025 Unchanged 210,000 0 (0.0%) 3.73% $4,935,000 2025-11-13
Q2 2025 Reduced 210,000 -5 (0.0%) 2.37% $2,383,500 2025-08-14
Q1 2025 Added 210,005 +5 (0.0%) 1.21% $1,396,533 2025-05-15
Q4 2024 Unchanged 210,000 0 (0.0%) 1.88% $2,316,300 2025-02-14
Q3 2024 Unchanged 210,000 0 (0.0%) 2.23% $2,580,900 2024-11-14
Q2 2024 Unchanged 210,000 0 (0.0%) 2.62% $2,837,100 2024-08-13
Q1 2024 Unchanged 210,000 0 (0.0%) 2.31% $2,835,000 2024-05-14
Q4 2023 Added 210,000 +125,000 (147.1%) 0.86% $1,104,600 2024-02-14
Q3 2023 Unchanged 85,000 0 (0.0%) 0.28% $334,900 2023-11-14
Q2 2023 Added 85,000 +70,000 (466.7%) 0.68% $903,550 2023-08-08
Q1 2023 Unchanged 15,000 0 (0.0%) 0.1% $125,000 2023-05-12
Q4 2022 Unchanged 15,000 0 (0.0%) 0.1% $138,000 2023-02-03
Q3 2022 Unchanged 15,000 0 (0.0%) 0.14% $193,000 2022-11-07
Q2 2022 Unchanged 15,000 0 (0.0%) 0.14% $198,000 2022-08-12
Q1 2022 Unchanged 15,000 0 (0.0%) 0.23% $316,000 2022-05-13
Q4 2021 Unchanged 15,000 0 (0.0%) 0.23% $360,000 2022-02-14
Q3 2021 Unchanged 15,000 0 (0.0%) 0.26% $382,000 2021-11-12
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

196 managers reported STOKE THERAPEUTICS INC COM for Q4 2025.

Managers reporting STOKE THERAPEUTICS INC COM in Q4 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Reduced 5,600,920 -1,264,137 < 0.01% $177,773,201 27 qtrs
RTW INVESTMENTS LP Added 5,546,856 +423,331 1.76% $176,057,209 27 qtrs
Lynx1 Capital Management LP Unchanged 5,404,674 0 34.73% $171,544,353 10 qtrs
BlackRock Inc Reduced 5,212,554 -774,887 < 0.01% $165,446,463 6 qtrs
Redmile Group LLC Reduced 4,034,070 -141,472 9.43% $128,041,382 27 qtrs
MORGAN STANLEY Added 3,546,158 +9,108 < 0.01% $112,555,054 27 qtrs
BAKER BROS ADVISORS LP Reduced 3,336,697 -1,297,141 0.62% $105,906,763 14 qtrs
TORONTO DOMINION BANK Unchanged 3,173,258 0 0.15% $100,719,209 5 qtrs
VANGUARD GROUP INC Reduced 3,149,239 -14,635 < 0.01% $99,956,846 27 qtrs
STATE STREET CORPORATION Added 2,498,049 +1,072,176 < 0.01% $79,288,075 26 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2025
Filed
February 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
260,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.